Article

Estimated Costs for Duchenne Muscular Dystrophy Care in Brazil

2023-03-15

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> The economic burden of rare diseases on health systems is still not widely measured, with the generation of accurate information about the costs with medical care for subjects with rare diseases being crucial when defining health policies. Duchenne Muscular Dystrophy (DMD) is the most common form of muscular dystrophy, with new technologies recently being studie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d22cb58e-f687-573a-9ead-f9b5b129ac76
DOI: 10.21203/rs.3.rs-2335060/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Estimated Costs for Duchenne Muscular Dystrophy Care in BrazilDOI 10.21203/rs.3.rs-2335060/v1Read

Estimated costs for Duchenne muscular dystrophy care in BrazilSemantic proximity Read

Household costs in the United States for accommodating functional impairments associated with Duchenne muscular dystrophy: results from a caregiver surveySemantic proximity Read

Social difficulties and costs/burden of adult Duchenne muscular dystrophy in Japan: A questionnaire survey based on the Japanese Registry of Muscular Dystrophy (Remudy)Semantic proximity Read

Out-of-Pocket Healthcare Expenditures of Households Living With Rare DiseasesSemantic proximity Read

Spinal Muscular Atrophy: The High Costs of Innovative Therapies for Rare DiseasesSemantic proximity Read

Epidemiology and economic burden of selected rare genetic diseases in Germany – a claims database studySemantic proximity Read

Rare Disease Curative Care Expenditure- Financing Scheme-Health Provider- Beneficiary Group Analysis — An Empirical Study in Sichuan Province, ChinaSemantic proximity Read

[The cost of specialized medical care of children under spinal muscular atrophy in Moscow].Semantic proximity Read

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesSemantic proximity Read

Is it ethical to reimburse “SMA Innovative Treatments” from government resources?Semantic proximity Read

Healthcare resource utilization of patients with mitochondrial disease in an outpatient hospital settingSemantic proximity Read

Quality of Life and Financial Burden in Duchenne Muscular Dystrophy in Greece: Insights into Health System Performance in the Post-Pandemic ContextSemantic proximity Read